kabutan

Meiji Holdings Co., Ltd.(2269) Summary

2269
TSE Prime
Meiji Holdings Co., Ltd.
3,229.0
JPY
-31.0
(-0.95%)
Dec 5, 11:30 am JST
20.82
USD
Dec 4, 9:30 pm EST
Result
PTS
outside of trading hours
3,229.8
Dec 5, 11:29 am JST
Summary Chart Historical News Financial Result
PER
16.2
PBR
1.17
Yield
3.25%
Margin Trading Ratio
5.26
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
3,250.0 JPY 20.95 USD
Previous Close Dec 4
3,260.0 JPY 20.98 USD
High Dec 5, 9:00 am
3,260.0 JPY 21.01 USD
Low Dec 5, 9:14 am
3,217.0 JPY 20.73 USD
Volume
446,800
Trading Value
1.44B JPY 9.31M USD
VWAP
3231.79 JPY 20.84 USD
Minimum Trading Value
322,900 JPY 2,082 USD
Market Cap
0.91T JPY 5.88B USD
Number of Trades
1,247
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
2,786
1-Year High Feb 10, 2025
20,343
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 140,100 312,600 2.23
Nov 21, 2025 440,700 460,400 1.04
Nov 14, 2025 82,700 546,900 6.61
Nov 7, 2025 84,900 660,500 7.78
Oct 31, 2025 86,200 824,300 9.56
Company Profile
Meiji Holdings Co., Ltd. was formed through the integration of Meiji Seika and Meiji Dairies. It is the largest company in the confectionery and dairy industries. The company's pharmaceutical business is experiencing rapid growth, and it is expanding globally.
Sector
Foods
Meiji Holdings Co., Ltd. operates in two business segments: Food and Pharmaceuticals. In the Food segment, the company handles a wide range of products including dairy products, confectioneries, nutritional foods, and animal feed, conducting business through numerous subsidiaries and affiliated companies both domestically and internationally. The Pharmaceutical segment focuses primarily on prescription drugs and veterinary medicines, manufacturing and selling these products through domestic and overseas subsidiaries. As a pure holding company, Meiji Holdings is responsible for formulating group-wide strategies and managing operations. Meiji Co., Ltd. is positioned as the core company in the food business, while Meiji Seika Pharma Co., Ltd. and KM Biologics Co., Ltd. are the core companies in the pharmaceutical business. The company is also focusing on global expansion, with numerous overseas subsidiaries, particularly in Asia.